Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)

ConditionPreeclampsia (PE)

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age18+

SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The purpose of this study is to determine whether first-trimester screening for preeclampsia based on the FMF algorithm (a combination of maternal clinical, sonographic and biochemical parameters), improves maternal or perinatal health.

Eligibility criteria

Qualifiers

Pregnancy between 11 and 14 WG

Age ≥18 years

Affiliated to or beneficiary of a health insurance system (including AME)

Signed informed consent

Disqualifiers

Gestational age <11 WG or >14 WG

Known ectopic pregnancy

Known non-ongoing pregnancy

Known multiple pregnancy

Trial design

Treatments tested in this trial

First-trimester preeclampsia screening (FMF triple test)

Treatment groups

14,500 Participants

are divided into 2 treatment groups

Locations22

Select a site below to view it on the map.

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

INSERM, Epopé team

Collaborator

URC-CIC Paris Descartes Necker Cochin

Collaborator

Source ClinicalTrials.gov